Eisai Co. Ltd.

In News

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan | News Release：2025 | Eisai Co., Ltd. - Eisai Co., Ltd.

Eisai Co., Ltd. - Jun 02, 2025

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China - Biogen

Biogen - Jan 06, 2026

Why It Might Not Make Sense To Buy Eisai Co., Ltd. (TSE:4523) For Its Upcoming Dividend - simplywall.st

simplywall.st - Sep 25, 2025

The Truth About Eisai Co Ltd: Is This Alzheimer’s Stock the Next Big Flex or a Fade? - AD HOC NEWS

AD HOC NEWS - Jan 07, 2026

Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China - Eisai Co., Ltd.

Eisai Co., Ltd. - Aug 18, 2025

Eisai Co., Ltd. 2026 Q1 - Results - Earnings Call Presentation (OTCMKTS:ESALF) 2025-08-05 - Seeking Alpha

Seeking Alpha - Aug 05, 2025

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug - Reuters

Reuters - Aug 29, 2025

EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - FinancialContent

FinancialContent - Jan 07, 2026

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 - PR Newswire

PR Newswire - Dec 03, 2025

History of Enhancing the Company's Corporate Governance - Eisai Co., Ltd.

Eisai Co., Ltd. - May 16, 2025

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease - PR Newswire

PR Newswire - Oct 06, 2025

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China - Biogen

Biogen - Sep 28, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment